These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26205685)

  • 1. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis.
    Laoutidis ZG; Kioulos KT
    Pharmacopsychiatry; 2015 Sep; 48(6):187-99. PubMed ID: 26205685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
    Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
    Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
    Carrasco JL; Kornstein SG; McIntyre RS; Fayyad R; Prieto R; Salas M; Mackell J; Boucher M
    Int Clin Psychopharmacol; 2016 May; 31(3):134-46. PubMed ID: 26895080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.
    Soares CN; Zhang M; Boucher M
    CNS Spectr; 2019 Jun; 24(3):322-332. PubMed ID: 29140227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.
    Clayton AH; Hwang E; Kornstein SG; Tourian KA; Cheng RF; Abraham L; Mele L; Boucher M
    Int Clin Psychopharmacol; 2015 Nov; 30(6):307-15. PubMed ID: 26230270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.
    Coleman KA; Xavier VY; Palmer TL; Meaney JV; Radalj LM; Canny LM
    CNS Spectr; 2012 Sep; 17(3):131-41. PubMed ID: 22883424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder.
    Soares CN; Wajsbrot DB; Boucher M
    CNS Spectr; 2020 Jun; 25(3):363-371. PubMed ID: 31060632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor].
    Alcantara-Montero A
    Rev Neurol; 2017 Mar; 64(5):219-226. PubMed ID: 28229443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability.
    Xu Y; Bai SJ; Lan XH; Qin B; Huang T; Xie P
    Braz J Med Biol Res; 2016 May; 49(6):. PubMed ID: 27240293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine in the treatment of major depression: an updated overview.
    Norman TR; Olver JS
    Expert Opin Pharmacother; 2021 Jun; 22(9):1087-1097. PubMed ID: 33706624
    [No Abstract]   [Full Text] [Related]  

  • 14. Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.
    Wu L; Gerdts EA; Alam A
    Prim Care Companion CNS Disord; 2019 Jan; 21(1):. PubMed ID: 30664338
    [No Abstract]   [Full Text] [Related]  

  • 15. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.
    Lense XM; Hiemke C; Funk CSM; Havemann-Reinecke U; Hefner G; Menke A; Mössner R; Riemer TG; Scherf-Clavel M; Schoretsanitis G; Gründer G; Hart XM
    Psychopharmacology (Berl); 2024 Feb; 241(2):275-289. PubMed ID: 37857898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial.
    Reddy S; Fayyad R; Edgar CJ; Guico-Pabia CJ; Wesnes K
    J Psychopharmacol; 2016 Jun; 30(6):559-67. PubMed ID: 27009044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
    McIntyre RS; Fayyad R; Mackell JA; Boucher M
    Curr Med Res Opin; 2016; 32(3):587-99. PubMed ID: 26709542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
    J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
    Perry R; Cassagnol M
    Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper.
    Sampogna G; Caraci F; Carmassi C; Dell'Osso B; Ferrari S; Martinotti G; Sani G; Serafini G; Signorelli MS; Fiorillo A
    Expert Opin Pharmacother; 2023; 24(14):1511-1525. PubMed ID: 37450377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.